Theorem Clinical Research has signed a deal with Biomedical Systems to expands its testing services, enlisting a partner with expertise in diagnostics.
Taking a page from famed partners like Sanofi and Regeneron and Roche and Genentech, Merck has signed a sweeping R&D deal with biotech NGM Biopharmaceuticals, promising up to $450 million for 5 years of pipeline-building collaboration.
AnGes MG has formed a new partnership with Mitsubishi Tanabe Pharma Corporation for the marketing of investigational gene therapy Collategene (beperminogene perplasmid) in Japan, ending ties with Daiichi Sankyo.
China FDA has issued draft guidelines on changes to good clinical practice guidelines that cover 34 provisions, including the use of outsourced partners in China that are generally in line with international aims of harmonization.
Indian drugmaker Lupin announced two separate developments in its asthma drug delivery segment, launching one product in the U.S. and signing a development agreement for a generic version of GlaxoSmithKline's Advair Diskus, which would be commercialized in North America and other markets.
Sanofi has inked a discovery-stage agreement in hopes of developing a fleet of new autoimmune disease treatments, homing in on a novel pathway alongside a Dutch biotech.
China sequencing giant BGI has had studies published recently having to do with things as deep as detecting novo mutations responsible for most genetic diseases to something as ordinary, yet important, as a prenatal genetic test it calls NIFTY that is nearly 100% accurate.
FiercePharmaAsia rounds up company activity in Asia across pharmaceuticals, biotech and devices to stay abreast of deal making and provide insight on partnerships and disputes in the works.
Rainbow Medical will open an office in Shanghai to help facilitate strategic deals as part of a $25 million cash infusion from investors in China. The firm is an Israeli-based seed investor and incubator specifically for medical device and medical technology startups.
Alzheimer's Research UK is setting up a trio of discovery units in the Golden Triangle with plans to recruit dozens of investigators to advance new work on therapeutics for the memory-robbing disease.